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Abstract
Background: There is need for a cognitive test battery that can be easily used in clinical practice to detect or
monitor cognitive performance in patients with multiple sclerosis (MS). In order to conduct, in this patient group, a
preliminary investigation of the validity and utility of a brief computerized battery, the Cognitive Drug Research
(CDR) battery, we longitudinally assessed cognition in patients with relapsing remitting (RR) MS.
Methods: Forty-three mildly disabled, clinically active RRMS patients were repeatedly assessed with the Digit
Symbol Substitution Test (DSST), Paced Auditory Serial Addition Test (PASAT) and five composite scores derived
from the CDR computerized cognitive test system (CDR System): Power of Attention, Continuity of Attention,
Quality of Working Memory, Quality of Episodic Memory and Speed of Memory. The Multiple Sclerosis Functional
Composite (MSFC) and Expanded Disability Status Scale (EDSS) measured disability.
Results: The composite scores from the CDR battery generally showed excellent test-retest reliability over the
repeated assessments, though was low on occasions for the Quality of Working Memory and Quality of Episodic
Memory measures. The CDR measures tended to be highly correlated with other measures of cognition (DSST and
PASAT) and were also strongly related to disability (EDSS and MSFC). Baseline scores indicated large impairments to
visual information processing speed and attention (DSST, Cohen’s d 1.1; Power of Attention d 1.4 [reaction time on
tasks of focussed and sustained attention]), and a moderate impairment both to sustained attention (Continuity of
Attention d 0.6) and complex information processing speed (Speed of memory d 0.7 [reaction time on tasks of
working and episodic Memory]), when compared to normative data derived from healthy volunteers enrolled in a
series of separate, prior clinical trials. Working memory (Quality of Working Memory) and episodic memory (Quality
of Episodic Memory) were unimpaired.
Conclusions: Preliminary validation of the CDR System indicated that for most, but not all measures psychometric
properties were adequate and the measures were related to disability (EDSS and MSFC) and other measures of
cognition.
Background
Cognitive disturbances are increasingly being recognized
as a prominent feature of multiple sclerosis (MS) [1],
occurring in about half of all patients [2] and in one
third of patients with early relapsing remitting MS
(RRMS) [3]. Impaired cognition is moderately associated
with total lesion volumes [4], cortical lesions [5] and
increase of cortical lesions over time on magnetic reso-
nance imaging (MRI) [6]. More robust correlations have
been found between cognitive function and whole brain
atrophy [7,8] and regional gray matter atrophy [9]. The
most frequently impaired domains are complex atten-
tion, information processing speed, memory and execu-
tive functions [3,10,11]. MS patients with problems in
cognitive performance have increased odds of becoming
unemployed [2]. Importantly, cognitive symptoms in
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[12], and in benign RRMS failure on neuropsychological
tests predicts clinical worsening over a 3-year period
[13].
Two widely used and recommended neuropsychologi-
cal test batteries have been developed for use in research
and care of MS patients. The Brief Repeatable Neuropsy-
chological Battery (BRNB) [14,15], which includes the
Selective Reminding Test (SRT) [auditory/verbal mem-
ory], Controlled Oral Word Association (COWAT) [lan-
guage], Paced Auditory Serial Addition Test (PASAT)
[auditory processing speed, working memory], Symbol
Digit Modalities Test (SDMT) [visual processing speed,
working memory], and the 10/36 Spatial Recall Test
[visuo-spatial memory]. This battery has alternate forms
and has been validated in several cultures and languages.
A second battery, the Minimal Assessment of Cognitive
Functioning in Multiple Sclerosis (MACFIMS) [16], was
the result of a consensus conference and is an expansion
of the BRNB, replacing the 10/36 with the Brief Visuos-
patial Memory Test-Revised (BVMTR) and the SRT with
the California Verbal Learning Test-Second Edition
(CVLT2), which have more established psychometric
properties, in particular with respect to alternate forms
and test-retest reliability. In addition, the MACFIMS
includes the Delis-Kaplan Executive Functioning System
(D-KEFS) Sorting Test [executive function] and the Judg-
ment of Line Orientation Test [spatial function].
Despite their status as well established batteries,
further development in this area is warranted due to
several factors, particularly in respect of the utility of
BRNB and MACFIMS in clinical trials and patient care.
Rater and patient burden are high, with the MACFIMS
taking around 90 minutes to administer and both bat-
teries containing a series of component tests and scores.
These batteries require a high degree of expertise and
standardized administration, and scoring may be diffi-
cult in large scale, multicentre, multi-national clinical
trials. Perhaps of most importance, the batteries include
no measurement of reaction time. In a disease where
information processing speed during cognitive tasks is
recognized as one of the primary deficits, the measures
are not capable of separating information processing
speed from other aspects of task performance. For
example, impairment of motor function, information
processing speed or working memory might affect Digit
Symbol Substitution Test (DSST)/SDMT or PASAT
scores; information processing speed or language or
executive search impairment might affect COWAT
scores; and information processing speed or memory
impairment might affect SRT, CVLT2, 10/36 and
BVMTR scores. However, these tasks cannot differenti-
ate selective impairment of the different functions,
which contribute to overall performance.
The Cognitive Drug Research (CDR) System is a brief,
multiple repeatable, computerized battery of cognitive
tests (http://www.unitedbiosource.com) [17,18]. Multiple
alternate forms and availability in several languages make
the battery suited to multi-national clinical trials use.
The battery uses computer algorithms or rule sets to gen-
erate alternate forms of tests and randomizes these across
repeated assessments, such that at each time-point in a
study schedule each participant completes a different
form of the test. The use of a simple two button response
box minimizes the motor component of task perfor-
mance and facilitates its use in populations with impaired
motor control e.g. Parkinson’sd i s e a s e[ 1 7 ] .T h eC D R
System is modular, including tests of attention and infor-
mation processing speed (Simple reaction time, Choice
reaction time and Digit vigilance tasks), verbal and visuo-
spatial working memory (Numeric and Spatial working
memory tasks) and verbal and visual episodic memory
(Immediate and Delayed word recall [verbal responses
are recorded by the administrator], Word recognition
and Picture recognition tasks). Sensitivity indices (SI),
ranging from zero (chance performance) to one (perfect
accuracy), have been calculated for working memory and
recognition tasks [19].
In this study we investigated the validity and utility of
the CDR System by longitudinally assessing cognitive
performance in RRMS patients with the established
DSST and PASAT and comparing the results with those
obtained by the CDR System.
Methods
The study was performed in two general hospitals
(Amphia Ziekenhuis, Breda, the Netherlands; Clinique
St. Pierre, Ottignies, Belgium), one university hospital
(Cliniques Universitaires St. Luc, Université catholique
de Louvain, Brussels, Belgium) and two MS centres (MS
Centre Nijmegen, Nijmegen, the Netherlands; Centre
Neurologique et de Readaptation Fonctionnelle, Frai-
ture-en-Condroz, Belgium), and was ancillary to the
FLAIR study, an investigator-initiated, international
study on health-related quality of life (HR-QoL) and dis-
ability in RRMS patients during treatment with intra-
muscular (interferon-beta-1a INFb-1a) (ClinicalTrials.
gov identifier NCT00534261). Inclusion criteria were:
(1) RRMS, (2) age 18-70 years, inclusive, (3) two relapses
in the preceding 24 months, (4) disease duration at least
12 months, (5) EDSS 5.5 or less, (6) naive for INFb,( 7 )
written informed consent prior to any assessments not
part of routine care. Exclusion criteria and details on
study design and procedures have been reported [20].
The study was approved by the Independent Review
Board, Amsterdam, the Netherlands and carried out in
compliance with the Helsinki Declaration. The study
was funded by Biogen Idec Netherlands.
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Cognitive function was assessed using the DSST, the
PASAT with 3 sec. interval (PASAT 3”)[ p a r to ft h e
Multiple Sclerosis Functional Composite (MSFC)] and
the CDR computerized battery. The DSST is a widely
used measure of visual information processing speed
and working memory, complex visual scanning and sus-
tained attention [21]. The PASAT 3” measures proces-
sing speed and working memory in the auditory/verbal
sphere [22]. The CDR System is modular, and the
selected battery measured attention and psychomotor/
information processing speed (Simple reaction time,
Choice reaction time and Digit vigilance tasks - both
accuracy of responding and reaction time to visual sti-
mulus presentation), verbal and visuo-spatial working
memory (Numeric and Spatial working memory tasks)
and verbal and visual episodic memory (Immediate and
Delayed word recall, Word recognition and Picture
recognition tasks) (see Additional file 1); and took
around 15-20 minutes to complete. To minimize the
motor requirement in responding, patient responses
were recorded via a simple response box with two large
buttons, one marked ‘YES’ and one marked ‘NO’,i nt h e
patient’s own language. The patient was not required to
use the computer keyboard or mouse and in the word
recall tests, oral responses were recorded by the test
administrator. Five composite domain scores were
derived from the CDR battery: Power of Attention (a
measure of attention and psychomotor/information pro-
cessing speed summing reaction times from the Simple
reaction time, Choice reaction time and Digit vigilance
tasks), Continuity of Attention (a measure of attention
summing accuracy and error measures from the Choice
reaction time and Digit vigilance tasks), Quality of
Working Memory (a measure of working memory sum-
ming accuracy measures from the Numeric and Spatial
working memory tasks), Quality of Episodic Memory (a
measure of episodic memory summing accuracy mea-
s u r e sf r o mt h eI m m e d i a t ea n dD e l a y e dw o r dr e c a l l ,
Word recognition and Picture recognition tasks) and
Speed of Memory (a measure of complex information
processing speed summing reaction times from the
Numeric and Spatial working memory and Word and
Picture recognition tasks) [23] (see Additional file 2).
The average of z-scores for all individual task measures
yielded the CDR composite.
Disability was measured by the MSFC [average of z-
scores for PASAT 3”, Timed 25-Foot Walk (Timed-
25FWT) and 9-Hole Peg Test (9-HPT)] [24] and the
Expanded Disability Status Scale (EDSS) [25].
Physical and mental domains of HR-QoL were measured
by the Multiple Sclerosis Quality of Life-54 (MSQoL-54)
questionnaire. Scores for each domain range from 0 to
100, where higher values indicate better HR-QoL.
The CDR battery, the DSST and the MSFC were per-
formed at Day -60 (training), Day -30 (training), Day 0
(baseline), Day 30 and Months 3, 6, 12, 18 and 24.
MSQoL-54 scores were assessed at Day 0 and Months
3, 6, 12, 18 and 24, and the EDSS score on Day 0 and
Month 24. Training was performed prior to the baseline
assessment to familiarize patients with the procedures
and overcome initial learning/practice effects.
Statistical Analyses
Validity of the CDR battery was evaluated by asses-
sing: a) test-retest reliability (Pearson correlation
between subsequent assessments); b) practice effects
(using the ANOVA analyses from the model described
below); c) concurrent validity (Pearson correlation of
cognitive measures with Physical MSQoL-54, Mental
MSQoL-54 and EDSS scores at screening/baseline and
Month 24; and Pearson correlation between CDR cog-
nitive measures and DSST and MSFC measures at
screening/baseline and Month 24); and d) discriminant
validity (comparison to age-matched healthy controls,
mean age 33.4 years, standard deviation [SD] 12.35,
from the CDR normative database [version 3], derived
from volunteers enrolled in a series of prior clinical
trials). For the latter evaluation, the size of differences
in outcome between patients and healthy controls was
calculated using Cohen’sd .E f f e c ts i z e sm a yb ei n t e r -
preted as small (d ≥0.2), moderate (d ≥0.5) or large (d
≥0.8).
Correction for multiple comparisons was made using
the Bonferroni method at p = 0.05 for each set of ana-
lyses conducted (p-value following correction indicated
in the table legends).
An additional analysis was conducted to determine the
number of patients impaired on the CDR cognitive mea-
sures. Patients were classified as impaired if they were ≥
1 SD below normative data on three or more of the five
composite domain scores derived from the battery
(Power of Attention, Continuity of Attention, Quality of
Working Memory, Quality of Episodic Memory and
Speed of Memory). T-tests were used to evaluate level
of disability on the EDSS in impaired versus unimpaired
patients. The ANOVA assessing change over time was
repeated fitting impairment at Day -30 as a fixed effect
and the interaction term between time-point and
impairment.
Finally, analyses were conducted to assess the change
over time in cognitive parameters.Changes over time
were assessed using one-way analyses of covariance
using a mixed model (SAS
® PROC MIXED) with a
fixed effect term for time-point and a random effect
for patients. Comparisons between the time-points
were made using the t-test from the LSmeans
statement.
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Patient characteristics
Forty-three RRMS patients were studied, 30 female and
13 male. Mean age was 38.8 years (SD 10.5) and mean
E D S Ss c o r e2 . 8( S D1 . 1 5 ) .M e a nd i s e a s ed u r a t i o nw a s
6.0 years (SD 5.7), mean time since diagnosis 3.3 years
(SD 4.1), and mean annualized relapse rate over the
prior 24 months 1.2 (SD 0.4).
Test-retest reliability
For most cognitive measures test-retest reliability was
good (>0.7) and statistically significant. Exceptions were
Quality of Working Memory and Quality of Episodic
Memory, which showed lower and more variable corre-
lation coefficients (Tables 1 and 2).
Correlations of cognitive and MSFC measures with EDSS
and MSQoL-54
For EDSS at screening (Day -60) the largest correlation
coefficient was seen for Power of Attention (0.62), fol-
lowed by the CDR composite (0.59), and 9-HPT (0.55).
For EDSS at Month 24 the largest correlation coefficient
was seen for DSST (0.76), followed by the CDR compo-
site (0.61), and MSFC (0.56). For MSQOL-54 Physical at
screening the largest coefficient was seen for Timed 25-
FWT (0.35) and all correlations were non-significant and
small. For MSQOL-54 Physical at Month 24 the largest
correlation coefficient was seen for Quality of Episodic
Memory (0.64), followed by the Quality of Working
Memory (0.35), and Continuity of Attention (0.34) and
all correlations were non-significant. For MSQOL-54
Mental at screening the largest coefficient was seen for 9-
HPT (0.23) and all correlations were non-significant and
small. For MSQOL-54 Physical at Month 24 the largest
correlation coefficient was seen for Quality of Episodic
Memory (0.6), followed by the Quality of Working Mem-
ory (0.41), the CDR composite (0.25) and again all corre-
lations were non-significant (Table 3).
Correlations of CDR scores with DSST and MSFC measures
At baseline the CDR composite correlated well with the
DSST and the PASAT 3”,a sw e l la sw i t ht h e9 - H P Ta n d
the MSFC, as did Power of attention (Table 4). Correla-
tions with leg function (Timed 25-FWT) were less strong.
Baseline cognitive function
CDR and DSST data at baseline were compared to nor-
mative data (CDR data base version 3) derived from
healthy age matched volunteers, using data gathered in
a series of prior clinical trials. Effect size differences
(Cohen’sd )s h o w e dl a r g ei m p a i r m e n t st oP o w e ro f
Attention (d = 1.4) and DSST (d = 1.1), and moderate
impairments to Continuity of Attention (0.6) and Speed
of Memory (0.7). Quality of Working Memory and
Quality of Episodic Memory were unimpaired (Table 5).
Level of cognitive impairment
The number of patients with cognitive impairment,
defined as three or more domains ≥ 1 SD below age
matched normative data, was 14 at Day -30 (33%) and 16
(41%) at Month 24. Learning/practice effects may miss-
categorise a small number of patients if training/familiari-
sation is not conducted, with 17 patients (39.5%) categor-
ized as impaired at the initial Day -60 time-points. As
expected, the presence of cognitive impairment was asso-
ciated with a statistically significantly greater disability on
the EDSS (Table 5). Using cognitive impairment as a fixed
effect in the ANOVA model we showed, as would be
expected, a highly significant effect of impairment, with
the cognitively impaired patients performing more poorly
Table 1 Test-retest reliability between successive assessments
Day -60 to
-30
Day -30 to
0
Day 0 to
30
Day 30 to
Month 3
Month 3 to
6
Month 6 to
12
Month 12 to
18
Month 18 to
24
Power of Attention 0.90
p < 0.0001
0.90
p < 0.0001
0.90
p < 0.0001
0.92
p < 0.0001
0.94
p < 0.0001
0.92
p < 0.0001
0.90
p < 0.0001
0.86
p < 0.0001
Continuity of Attention 0.76
p < 0.0001
0.87
p < 0.0001
0.72
p < 0.0001
0.9
p < 0.0001
0.87
p < 0.0001
0.88
p < 0.0001
0.91
p < 0.0001
0.89
p < 0.0001
Quality of working
Memory
0.35
p = 0.0535
0.65
p < 0.0001
0.53
p = 0.0024
0.75
p < 0.0001
0.41
p < 0.0001
0.58
p = 0.0006
0.73
p < 0.0001
0.55
p = 0.0012
Quality of Episodic
Memory
0.52
p = 0.0262
0.7
p = 0.0012
0.5
p = 0.0331
0.73
p = 0.0006
0.66
p = 0.0027
0.82
p < 0.0001
0.69
p = 0.0015
0.7
p < 0.0001
Speed of Memory 0.92
p < 0.0001
0.95
p < 0.0001
0.88
p < 0.0001
0.91
p < 0.0001
0.88
p < 0.0001
0.89
p < 0.0001
0.83
p < 0.0001
0.84
p < 0.0001
CDR composite 0.92
p < 0.0001
0.95
p < 0.0001
0.94
p < 0.0001
0.97
p < 0.0001
0.9
p < 0.0001
0.93
p < 0.0001
0.93
p < 0.0001
0.96
p < 0.0001
DSST 0.97
p < 0.0001
0.96
p < 0.0001
0.96
p < 0.0001
0.96
p < 0.0001
0.96
p < 0.0001
0.96
p < 0.0001
0.96
p < 0.0001
0.96
p < 0.0001
CDR, Cognitive Drug Research, DSST, Digit Symbol Substitution Test. Correcting for multiplicity p-values are statistically significant at p < 0.0006.
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time-point and there was no support for cognitive impair-
ment at ‘baseline’ (Day -30) predicting subsequent decline
in cognition in these patients (Table 6).
Change over time
For several measures improvements occurred during the
screening phase, most notably for the PASAT 3” and
Quality of Working Memory, which showed statistically
significant main effects of time-point in the ANOVA
model. For Quality of Working Memory the LSmeans
comparisons between each time-point and the subse-
quent assessment showed a single statistically significant
difference between Day -60 and Day -30 (t 2.85 [300] p
= 0.0046). For PASAT 3” the LSmeans comparisons
between each time-point and the subsequent assessment
also showed a single statistically significant difference
between Day -60 and Day -30 (t 4.17 [266] p < 0.0001).
In general terms, changes were most marked between
Days -60 and -30 and indicated learning/practice effects.
The changes displayed a typical ‘power-curve’ with
increasingly smaller improvements over the repeated
assessments (Figures 1 and 2 and Table 7).
Discussion
The CDR System has previously been validated in
dementia [17] and traumatic brain injury [18], and is
used in a variety of disease states and cognitive disorders
Table 2 Test-retest reliability between successive assessments
Day -60 to -30 Day -30 to 0 Day 0 to Month 3 Month 3 to 6 Month 6 to 12 Month 12 to 18 Month 18 to 24
Timed 25-FWT 0.95
p < 0.0001
0.96
p < 0.0001
0.91
p < 0.0001
0.96
p < 0.0001
0.94
p < 0.0001
0.72
p < 0.0001
0.97
p < 0.0001
9-HPT 0.96
p < 0.0001
0.92
p < 0.0001
0.91
p < 0.0001
0.92
p < 0.0001
0.93
p < 0.0001
0.95
p < 0.0001
0.95
p < 0.0001
PASAT 3” 0.85
p < 0.0001
0.92
p < 0.0001
0.84
p < 0.0001
0.91
p < 0.0001
0.92
p < 0.0001
0.94
p < 0.0001
0.97
p < 0.0001
MSFC 0.96
p < 0.0001
0.96
p < 0.0001
0.93
p < 0.0001
0.96
p < 0.0001
0.95
p < 0.0001
0.9
p < 0.0001
0.98
p < 0.0001
Timed 25-FWT, Timed 25 Foot Walk Test; 9-HPT, 9 Hole Peg Test, PASAT 3”, Paced Auditory Serial Addition Test 3 sec.; MSFC, Multiple Sclerosis Functional
Composite. Correcting for multiplicity p-values are statistically significant at p < 0.0006.
Table 3 Correlations of cognitive and MSFC measures with physical and mental MSQOL-54 and EDSS at screening (Day
0) and Month 24
MSQOL-54 Physical MSQOL-54 Mental EDSS
Day 0 Month 24 Day 0 Month 24 Day -60 Month 24
Power of Attention 0.14
p = 0.4371
0.21
p = 0.2707
0.1
p = 0.5311
0.07
p = 0.6964
0.62
p < 0.0001
0.5
p = 0.0023
Continuity of Attention 0.16
p = 0.2395
0.34
p = 0.0755
0.04
p = 0.8276
0.04
p = 0.8132
0.43
p = 0.0062
0.53
p = 0.001
Quality of working Memory 0.06
p = 0.733
0.35
p = 0.0598
0.14
p = 0.3742
0.41
p = 0.017
0.48
p = 0.0018
0.37
p = 0.0276
Quality of Episodic Memory 0.01
p = 0.9654
0.64
p = 0.0034
0.02
p = 0.9028
0.6
p = 0.0029
0.33
p = 0.0422
0.35
p = 0.0892
Speed of Memory 0.18
p = 0.3038
0.42
p = 0.0239
0.02
p = 0.8819
0.19
p = 0.2949
0.45
p = 0.0035
0.43
p = 0.0092
CDR composite 0.19
p = 0.2711
0.47
p = 0.0412
0.13
p = 0.4107
0.25
p = 0.2676
0.59
p < 0.0001
0.61
p = 0.0015
DSST 0.24
p = 0.1618
0.27
p = 0.2395
0.09
p = 0.5748
0.06
p = 0.7577
0.47
p = 0.0028
0.76
p < 0.0001
Timed 25-FWT 0.35
p = 0.0373
0.27
p = 0.154
0.15
p = 0.343
0.07
p = 0.6786
0.0
p = 0.9764
0.49
p = 0.002
9-HPT 0.0
p = 0.9896
0.08
p = 0.6629
0.23
p = 0.12
0.08
p = 0.652
0.55
p = 0.0001
0.53
p = 0.0003
PASAT 3” 0.03
p = 0.8805
0.16
p = 0.411
0.07
p = 0.6612
0.06
p = 0.7142
0.4
p = 0.0071
0.42
p = 0.0091
MSFC 0.17
p = 0.3352
0.19
p = 0.3328
0.02
p = 0.9241
0.12
p = 0.4834
0.43
p = 0.0044
0.56
p = 0.0003
MSFC, Multiple Sclerosis Functional Composite; MSQOL-54, Multiple Sclerosis-54 Quality of Life; EDSS, Expanded Disability Status Scale; CDR, Cognitive Drug
Research, DSST, Digit Symbol Substitution Test; Timed 25-FWT, Timed 25 Foot Walk Test; 9-HPT, 9 Hole Peg Test, PASAT 3”, Paced Auditory Serial Addition Test 3
sec. Correcting for multiplicity p-values are statistically significant at p < 0.0008.
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demonstrate both efficacy and safety of drugs [26-28].
The battery uses alternate forms of tests and randomizes
these across repeated assessments. It is important to note
that these alternate forms have not been specifically eval-
uated to demonstrate equivalence i.e. that they are paral-
l e lf o r m s .H o w e v e r ,t h ef o r m sa r ea sf a ra sp o s s i b l e
conceptually equivalent and the use of randomization
prevents systematic bias in comparison between visits
when comparing between or within groups. In the pre-
sent study population, test-retest reliability was moderate
to high for most CDR measures and the measures corre-
lated with other assessments of cognition (DSST, PASAT
3”) as well as with disability, supporting the validity of
the battery in RRMS. With the exception of two mea-
sures test-retest ranged between 0.72 and 0.98 and thus
c o u l db ec o n s i d e r e dh i g h .T h et w om e a s u r e ss h o w i n g
more variable test-retest were Quality of working (0.35 to
0.75) and Quality of episodic memory (0.5 to 0.82). The
poorest of these might possibly be related to the learn-
ing/practice effects on the Quality of working memory
measure, as this was seen between the first and second
assessments, where the largest improvement occurred.
However, the possibility for non-equivalence of alternate
forms to influence test-retest must also be considered. It
was of note that the CDR measures were correlated with
t h em o r ew i d e l yu s e dP A S A T .T h eP A S A T ,a sac o m p o -
nent of both the MSFC, BRNB and MACFIMS, has been
extensively used to study cognition in MS and is thought
primarily to measure information processing speed defi-
cits [29]. The DSST, though not widely used in MS, is a
common cognitive test in which the patient copies sym-
bols paired with numbers against a time limit and is the
reverse of the SDMT, in which the patient copies num-
bers paired with symbols. The SDMT using verbal
responses is also included in the BRNB and MACFIMS
batteries and may measure similar aspects of cognitive
function to the PASAT and DSST, particularly informa-
tion processing speed; and has been proposed as a repla-
cement for the PASAT in the MSFC [30,31].
Importantly, ease of use and the automation of the
CDR System facilitate cognitive assessment in a daily
care setting, and electronic data capture and computer
systems validation enhance data quality. In comparison
to the BRNB and MACFIMS batteries, the selected CDR
battery was shorter in duration, reducing patient burden,
though it does not cover some aspects of function such
as visual recall and abstract problem solving; and com-
ponent measures do not need to be hand scored and
entered into datasets, reducing rater burden and making
the tests better suited to clinical trials or patient care.
Recently, another computerized battery, the Automated
Table 4 Correlations between CDR measures and DSST, MSFC component scores and MSFC at baseline
Power of
Attention
Continuity of
Attention
Quality of working
memory
Quality of episodic
memory
Speed of
memory
CDR
composite
DSST 0.61
p < 0.0001
0.49
p = 0.0009
0.33
p = 0.0333
0.25
p = 0.1068
0.55
p = 0.0001
0.7
p < 0.0001
Timed 25-
FWT
0.18
p = 0.236
0.23
p = 0.1465
0.31
p = 0.0424
0.14
p = 0.3678
0.15
p = 0.3217
0.17
p = 0.2673
9-HPT 0.55
p = 0.0001
0.32
p = 0.0368
0.12
p = 0.3767
0.16
p = 0.3035
0.4
p = 0.0076
0.48
p = 0.001
PASAT 3” 0.6
p < 0.0001
0.31
p = 0.0431
0.2
p = 0.2092
0.17
p = 0.2692
0.35
p = 0.0209
0.49
p = 0.0009
MSFC 0.61
p = 0.0001
0.39
p = 0.0095
0.29
p = 0.0549
0.09
p = 0.5752
0.42
p = 0.0056
0.52
p = 0.0003
CDR, Cognitive Drug Research; DSST, Digit Symbol Substitution Test; MSFC, Multiple Sclerosis Functional Composite; Timed 25-FWT, Timed 25-Foot Walk Test; 9-
HPT, 9 Hole Peg Test, PASAT 3”, Paced Auditory Serial Addition Test 3 sec. Correcting for multiplicity p-values are statistically significant at p < 0.0017.
Table 5 Cognition at baseline versus normative data
Mean (SD) d p
Measure Normative Data (N≥1688) RRMS (N = 43)
Power of Attention 1083 (107) 1228 (162) 1.4 <0.0001
Continuity of Attention 64 (11.3) 57.3 (11.9) 0.6 0.0006
Quality of Working Memory 1.78 (0.21) 1.82 (0.16) -0.2 0.1183
Quality of Episodic Memory 186 (53) 180 (56) 0.1 0.5296
Speed of Memory 3106 (698) 3589 (850) 0.7 0.0006
DSST^ 58.7 (17.8) 41.5 (9.6) 1.1 <0.0001
SD, Standard Deviation; d, Cohen’s d (effect size); RRMS, Relapsing Remitting Multiple Sclerosis; DSST, Digit Symbol Substitution Test. ^DSST Normative Data N =
151; < 0.3 small effect size; 0.3 to 0.7 moderate effect size; > 0.7 large effect size. Correcting for multiplicity p-values are statistically significant at p < 0.008.
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Page 6 of 11Table 6 Number of patients impaired by ≥ 1 SD on three or more cognitive domains from the CDR System
Patient Impaired in Three or More Cognitive Domains? Day -60 Month 24
N (%) EDSS mean (SD) N (%) EDSS mean (SD)
No 26 (60.5) 2.4 (1.15) 23 (59) 2.4 (1.46)
Yes 17 (39.5) 3.4 (0.84) 16 (41) 3.3 (1.27)
T-test on EDSS t 3.34 [40] p = 0.0018 t 2.06 [35] p = 0.0469
SD, Standard Deviation. Correcting for multiplicity p-values are statistically significant at p < 0.025.
CDR System domain scores: Power of Attention; Continuity of Attention; Quality of Working Memory; Quality of Episodic Memory; and Speed of Memory.
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Page 7 of 11Neuropsychological Assessment Metrics (ANAM), has
been reported to be sensitive to cognitive impairment in
MS patients [32]. In our study, the CDR battery identi-
fied impairment to information processing speed (d
Power of Attention 1.4, d Speed of Memory 0.7) and
attention (d Continuity of Attention 0.6) as compared to
control data. The size of these impairments was highly
consistent with prior findings in MS, in comparable cog-
nitive domains. A study in MS patients (N = 65) versus
controls (N = 46), identified impairment to visual pro-
cessing speed and working memory (d SDMT 1.3) and
auditory processing speed and working memory (d
PASAT 0.7 to 0.9) [2]. However, it should be noted we
compared the present data to normative data from
healthy volunteers combin e df r o mas e r i e so fp r i o r
industry sponsored clinical trials, as opposed to a
matched control sample gathered as part of the present
study. As such although age matched, the samples will
differ in respect of dimensions other than RRMS diag-
nosis that may be relevant to cognitive performance.
The CDR measures were correlated with disability
(EDSS), in particular Power of Attention and the CDR
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Figure 2 Z-score change for DSST, MSFC Components and MSFC (Z-score calculated as (X-mean)/SD at Day -60). DSST, Digit Symbol
Substitution Test; MSFC, Multiple Sclerosis Functional Composite; SD, standard deviation; Timed 25-FWT, Timed 25 Foot Walk Test; 9HPT, 9 Hole
Peg Test, PASAT 3”, Paced Auditory Serial Addition Test 3 sec.
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Page 8 of 11composite, which showed a comparable relationship to
the EDSS as the DSST and the MSFC, which incorpo-
rates both measures of cognitive function and arm and
leg function i.e. disability. In addition, those patients
characterized as cognitively impaired using the CDR
battery had greater disability scores on the EDSS (Table
6). However, associations with HR-QoL were weaker. As
expected, correlations were evident between the CDR
battery measures and other measures assessing aspects
of cognition (DSTT and PASAT 3”), but were not seen
with leg function (Timed 25-FWT).
The lack of impairment to memory in our patient
g r o u pw a sn o tc o n s i s t e n tw i t hp r i o rf i n d i n g si n d i c a t i n g
memory impairment to be prominent in MS. This could
reflect properties of the CDR memory measures them-
selves e.g. sensitivity and/or lacking in sufficient diffi-
culty. Alternatively, the study population might have
been different from that in other studies e.g. relatively
well educated with respect to the normative sample and
thus ‘cognitive reserve’ might account for the lack of
memory impairment. The CDR tasks of delayed and
immediate recall and Spatial working memory nominally
cover the same cognitive domains as tasks included in
the BRNB and MACFIMS, which have identified impair-
ments in MS patient populations. Thus, in conjunction
with findings which show heterogeneity in cognitive
impairment in MS [33], it is possible that the present
sample may have presented an atypical pattern of
impairment. Additionally, the CDR System has no mea-
sure of visual recall, as included in the MACFIMS and
that may be particularly sensitive in this population. It
would be important for future studies employing the
CDR System to collect data on education, employment
history and other potentially relevant demographics.
However, it should be noted that some patients were at
ceiling on accuracy measures for Spatial and Numeric
working memory, Word and Picture recognition and
PASAT 3”. Thus these tasks may not be sufficiently
challenging. A further issue which will need to be clari-
fied in future studies is a more complete clinical charac-
terization of the MS population to address other factors
that may also impact upon cognition such as depression
and fatigue. Thus a follow-up study in a larger sample
with extensively described demographic and clinical
variables is now necessary.
Practice effects are well known for the PASAT [34] and
were also marked for the Quality of Working Memory
from the CDR battery (Table 7). Our data confirm the
importance of ‘training’ sessions for cognitive assess-
ments prior to baseline [35,36], particularly in uncon-
trolled longitudinal studies, to overcome the large initial
improvement in performance between the first and sec-
ond administration of the tasks. Conclusions regarding
any treatment effect cannot be drawn due to the fact that
the assessments were conducted during an uncontrolled
observational study. Thus without suitable control arms,
it is not possible to differentiate potential treatment
effects from those of the disease and/or properties of the
measures themselves, over repeated assessments.
Conclusions
The CDR System measures of attention, psychomotor/
information processing speed, complex information pro-
cessing speed and a global composite, showed good psy-
chometric properties and were related to other
measures of cognition and to disability. The data pro-
vide initial evidence for the utility and validity of the
CDR System for use in MS clinical trials. To further
validate the CDR System, data will be required in larger
samples of patients with a more complete clinical and
demographic characterization and with comparison to
established cognitive/neuropsychological test batteries e.
g. BRNB or MACFIMS.
Additional material
Additional file 1: describes the CDR System tasks and outcome
measures
Additional file 2: describes the derivation of cognitive domain
scores
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